Kenvue Inc. KVUE

Kenvue Inc. es una empresa de salud para el consumidor. La compañía opera a través de tres segmentos: Autocuidado, Salud y Belleza de la Piel, y Salud Esencial. Las categorías de productos del segmento de Autocuidado incluyen tos, resfriado y alergias; cuidado del dolor; y otros autocuidados (salud digestiva, cesación del tabaquismo y otros). Las categorías de productos del segmento de Salud y Belleza de la Piel incluyen cuidado facial y corporal, cabello, sol y otros. Las categorías de productos del segmento de Salud Esencial incluyen cuidado bucal, cuidado del bebé y otros cuidados esenciales (salud de la mujer y cuidado de heridas). Su cartera diferenciada de marcas incluye Tylenol, Neutrogena, Listerine, Johnson’s, Band-Aid, Aveeno, Zyrtec y Nicorette. Tiene presencia global a través de la cual vende y distribuye su cartera de productos en más de 165 países en sus cuatro regiones. Su red incluye 114 centros de distribución y 38 centros de servicio al cliente en todas sus regiones. Sus subsidiarias incluyen JNTL (APAC) HoldCo 2 LLC y JNTL (APAC) HoldCo 2 LLC.

Con 58 acciones de KVUE (USD 1.008,62) habrías recibido USD 60,90 en dividendos en los últimos 12 meses.

• The Motley Fool 14 sept

  Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now

  Kenvue (KVUE) is highlighted as a smart high-yield dividend stock with a 4.68% dividend yield and 64 consecutive years of dividend increases, making it a Dividend King. The company, spun off from Johnson & Johnson three years ago, generates steady revenue from recession-resilient consumer healthcare brands like Tylenol and Neutrogena. However, uncertainty exists due to a pending acquisition by Kimberly-Clark (KMB), another Dividend King with a 5.23% yield.

  

• Zacks Investment Research 7 sept

  Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still Ahead

  Kenvue has secured shareholder approval and U.S. antitrust clearance for its planned Q4 2026 combination with Kimberly-Clark. However, the deal faces ongoing risks including weak Self Care segment performance, $8.5B debt burden, margin pressures from inflation and tariffs, restructuring costs, and pending litigation. Q2 results showed 3% sales growth but EPS missed estimates with adjusted gross margin declining 70 basis points.

  

• Zacks Investment Research 7 sept

  Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?

  Kenvue Inc. (KVUE) demonstrated improved profitability in the first half of 2026, with adjusted operating margins rising 180 basis points to 23.1% and earnings climbing 18.9%, driven primarily by cost-cutting initiatives. However, organic sales growth remained modest at 1.2%, with the Self Care segment struggling while Skin Health and Beauty showed stronger performance. The company faces headwinds from tariffs, inflation, and $8.5 billion in debt, with a pending merger with Kimberly-Clark expected to close in Q4 2026.

  

• GlobeNewswire Inc. 2 sept

  Global Skin Care Products Market is Expected to Surpass the USD 260 Billion Mark by 2034 | DelveInsight

  The global skin care products market is projected to grow from USD 166 billion in 2025 to USD 262 billion by 2034, with a CAGR of approximately 5%. Growth is driven by rising consumer awareness of skin health, increasing disposable incomes, demand for premium and personalized products, and the influence of social media trends. Asia-Pacific leads with 38% market share, while North America is the fastest-growing region. Key players include L'Oréal, Unilever, Procter & Gamble, and Estée Lauder.

  

• The Motley Fool 24 ago

  This Consumer Staples Giant's Dividend Streak Rivals PepsiCo. Nobody Talks About It.

  Kimberly-Clark is an overlooked Dividend King with a 54-year consecutive dividend increase streak matching PepsiCo's. Despite lower brand recognition, KMB offers a higher yield (4.7% vs 4.1%), more resilient demand for household products, and is acquiring Kenvue to enhance its global portfolio, making it an attractive option for income-focused investors.